• CSE: DTC
  • FSE: DTC
  • USOTC: DTCFF
  • Download our Corporate Deck
  • GER
  • ENG
Defence Therapeutics
  • About Us
    • Our Model
    • Leaders & Partnerships
  • Accum Technology
    • Platform Technology
    • Cancer Therapeutics
    • Vaccine Development
  • Investors
  • News
  • Contact
Select Page
Defence’s Broad and Versatile Accum® Technology Platform Focus on Cancer Therapeutics

Defence’s Broad and Versatile Accum® Technology Platform Focus on Cancer Therapeutics

by FiveSenses | Sep 12, 2023 | News Release

Vancouver, BC, Canada, September 12th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various...
Defence’s Innovative Therapeutics are Featured on Viewpoint with Dennis Quaid 

Defence’s Innovative Therapeutics are Featured on Viewpoint with Dennis Quaid 

by FiveSenses | Sep 5, 2023 | News Release

Vancouver, BC, Canada, September 5, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational...
Defence Successfully Completes The First Milestone of its Collaboration Agreement with Orano

Defence Successfully Completes The First Milestone of its Collaboration Agreement with Orano

by Defence Therapeutics | Jul 18, 2023 | News Release

Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA...
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology

Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology

by FiveSenses | Jul 4, 2023 | News Release

Vancouver, BC, Canada, July 4, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint...
Defence Patent Portfolio at the Forefront of Success

Defence Patent Portfolio at the Forefront of Success

by FiveSenses | Jun 28, 2023 | News Release

Vancouver, BC, Canada, June 28, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is...
Defence Manufacturing of Accutox™ CGMP Final Drug Product Optimization for its Phase I Clinical Trial at City of Hope

Defence Manufacturing of Accutox™ CGMP Final Drug Product Optimization for its Phase I Clinical Trial at City of Hope

by Defence Therapeutics | Jun 16, 2023 | News Release

Vancouver, BC, Canada, June 16th 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached...
Defence Begins Testing it’s Arm Vaccine Against Pancreatic Cancer

Defence Begins Testing it’s Arm Vaccine Against Pancreatic Cancer

by FiveSenses | Jun 6, 2023 | News Release

Vancouver, BC, Canada, June 6, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated...
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

by Defence Therapeutics | May 30, 2023 | News Release

Vancouver, BC, Canada, May 26th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in...
Breakthrough Results: Defences Arm Vaccine Cured 100% of Animals with Pre-established Lymphoma

Breakthrough Results: Defences Arm Vaccine Cured 100% of Animals with Pre-established Lymphoma

by FiveSenses | May 24, 2023 | News Release

Vancouver, BC, Canada, May 24th 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful...
Defence’s Successful Accutox™ Pre-Clinical Efficacy Study Complete Ready for Phase I and Filing

Defence’s Successful Accutox™ Pre-Clinical Efficacy Study Complete Ready for Phase I and Filing

by FiveSenses | May 2, 2023 | News Release

Vancouver, BC, Canada, May 2nd, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immuneoncology vaccines and drug delivery technologies is please to announce the successful...
« Older Entries

Recent Posts

  • Defence’s Broad and Versatile Accum® Technology Platform Focus on Cancer Therapeutics
  • Defence’s Innovative Therapeutics are Featured on Viewpoint with Dennis Quaid 
  • Defence Successfully Completes The First Milestone of its Collaboration Agreement with Orano
  • Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology
  • Defence Patent Portfolio at the Forefront of Success

Recent Comments

    Archives

    • September 2023
    • July 2023
    • June 2023
    • May 2023
    • April 2023

    Categories

    • News Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Stock

    CSE: DTC
    FSE: DTC
    USOTC: DTCFF

    Contact

    (514) 947 – 2272
    info@defencetherapeutics.com

    1680 – 200 Burrard Street, Vancouver, BC, V6C 3L6

    Copyright © 2020. Defence Therapeutics. All Rights Reserved. / Web Design by Five Senses Branding